Medication for Addiction in Jail and Prison

Can you get Suboxone or methadone in jail or prison?

It depends entirely on where someone is held. There is no single national answer: availability of medication for opioid use disorder in jails and prisons varies widely, and many facilities still provide little or none, while a growing number now offer it. The medications themselves are the same three used in the community — methadone, buprenorphine, and naltrexone 1Ref 1Substance Abuse and Mental Health Services Administration (2021).TIP 63: Medications for Opioid Use Disorder — Full Document.That the three FDA-approved medications for opioid use disorder are methadone, buprenorphine, and naltrexone..

Because access differs so much by county and state, the practical questions are specific ones: does this facility continue a medication someone was already prescribed, does it start medication during incarceration, and does it connect people to a prescriber at release? A family member, a defense attorney, or the facility's medical unit is usually the fastest way to learn a given system's policy. There is no universal rule — access to medication for addiction behind bars is set facility by facility.

Why forced withdrawal behind bars is dangerous

When a jail stops someone's medication or offers no treatment, the result is enforced abstinence — and enforced abstinence lowers opioid tolerance. That is not a return to safety; it is a setup for overdose. Research on people leaving prison found that overdose risk is sharply elevated in the first weeks after release, driven in large part by lost tolerance during incarceration meeting a return to use 2Ref 2Binswanger IA, Nowels C, Corsi KF, et al. (2012).Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors.That overdose risk is sharply elevated in the first weeks after release from incarceration, driven in part by lowered tolerance during enforced abstinence..

The scale of the protection lost is large. A meta-analysis of cohort studies found that being retained on methadone or buprenorphine is associated with far lower all-cause and overdose mortality than being out of treatment 3Ref 3Sordo L, Barrio G, Bravo MJ, et al. (2017).Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.That retention on methadone or buprenorphine is associated with substantially lower all-cause and overdose mortality than being out of treatment.. Interrupting maintenance medication at the jailhouse door removes exactly the thing that was keeping someone alive.

What the medical standard of care says

The national practice guideline is unambiguous: opioid use disorder should be treated with methadone or buprenorphine rather than withdrawal management alone, medication should not be arbitrarily time-limited, and it should not be withheld from someone who is still using other substances 4Ref 4American Society of Addiction Medicine (2020).The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update.That the guideline recommends methadone or buprenorphine over withdrawal management alone, that medication should not be arbitrarily time-limited, and that it should not be withheld because of ongoing use of other substances.. None of that carves out an exception for people who are incarcerated.

This is why continuing medication-assisted treatment through a jail or prison stay, rather than forcing a taper, reflects the same evidence that governs care in any clinic. Where a facility declines to provide it, the gap is a policy and resource gap, not a medical judgment that the treatment stopped working. Families sometimes find it useful to have documentation of an existing prescription ready at intake.

The same guideline is also clear that medication should not be withheld from someone who is still using other substances, and that treatment should not be arbitrarily cut short 4Ref 4American Society of Addiction Medicine (2020).The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update.That the guideline recommends methadone or buprenorphine over withdrawal management alone, that medication should not be arbitrarily time-limited, and that it should not be withheld because of ongoing use of other substances.. Those principles matter inside a jail, where the temptation to treat abstinence as the default can be strongest and where the consequences of getting it wrong land hardest at the moment of release.

The window after release is the most dangerous

If there is one thing to plan around, it is the reentry window. The days and weeks immediately after release carry the highest overdose risk of the whole cycle, because tolerance built up before incarceration is gone and the body can no longer handle an amount that once felt routine 2Ref 2Binswanger IA, Nowels C, Corsi KF, et al. (2012).Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors.That overdose risk is sharply elevated in the first weeks after release from incarceration, driven in part by lowered tolerance during enforced abstinence.. A dose that seemed ordinary before jail can be fatal after.

This is why continuity matters more than almost anything else: leaving custody already connected to a prescriber, or with medication restarted, closes the most dangerous gap. Naloxone, the opioid-overdose reversal medication, is worth having on hand at release for anyone at risk and for the people around them. Overdose risk is highest in the first weeks after release from incarceration 2Ref 2Binswanger IA, Nowels C, Corsi KF, et al. (2012).Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors.That overdose risk is sharply elevated in the first weeks after release from incarceration, driven in part by lowered tolerance during enforced abstinence..

How methadone and buprenorphine are regulated

Understanding the rules helps explain why access looks the way it does. Methadone for addiction is dispensed only through federally regulated opioid treatment programs, while buprenorphine can be prescribed in an ordinary medical office. In 2024 a federal final rule expanded access — including more flexibility for take-home doses, telehealth initiation, and removing an older requirement that a person have a year of addiction before admission 5Ref 5Substance Abuse and Mental Health Services Administration (2024).42 CFR Part 8 Final Rule.That methadone for addiction is dispensed through federally regulated opioid treatment programs, and that the 2024 final rule expanded access including take-home doses, telehealth initiation, and removing the prior one-year admission requirement..

Those changes matter for reentry because they make it easier to restart or continue treatment quickly on the outside. They do not, by themselves, require any jail to provide medication; correctional health policy is set separately. But they widen the door someone walks through once released, which is the door that closes the post-release risk window.

Finding treatment for reentry, and paying for it

Planning the first appointment before release is the single most protective step, and there are neutral, free tools for it. FindTreatment.gov is the federal government's confidential, anonymous locator of state-licensed treatment facilities, and it can help identify programs and buprenorphine prescribers in a given area 6Ref 6Substance Abuse and Mental Health Services Administration (2024).FindTreatment.gov.That FindTreatment.gov is the federal government's free, confidential, anonymous locator of state-licensed treatment facilities.. It is a public data source, not a marketing helpline, which is exactly why it is worth using.

Cost is a common worry, but many communities have public and low- or no-cost options funded through federal and state programs, and Medicaid covers addiction treatment in most states. Working through the SAMHSA buprenorphine practitioner locator or a reentry caseworker before the release date turns a dangerous gap into a scheduled handoff. A useful move is to have the appointment booked, not just intended, for the day of or the day after release.

The most important thing is that the plan is concrete before the gate opens. A locator search done from inside, an appointment confirmed, a way to get there, a supply of naloxone, and someone on the outside who knows the plan — each of these closes a little more of the gap that the release window opens 6Ref 6Substance Abuse and Mental Health Services Administration (2024).FindTreatment.gov.That FindTreatment.gov is the federal government's free, confidential, anonymous locator of state-licensed treatment facilities.. The difference between intending to get treatment and having it scheduled is, in the first weeks after release, the difference that the mortality data keeps pointing to 3Ref 3Sordo L, Barrio G, Bravo MJ, et al. (2017).Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.That retention on methadone or buprenorphine is associated with substantially lower all-cause and overdose mortality than being out of treatment..